J 2010

Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children

ŽUREK, Jiří; Ludmila BARTLOVÁ; Lukáš MAREK a Michal FEDORA

Základní údaje

Originální název

Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children

Název česky

Sérový protein S100B jako molekulární marker závažnosti poranění mozku u dětí

Název anglicky

Serum S100B Protein as a Molecular Marker of Severity in Traumatic Brain Injury in Children

Autoři

ŽUREK, Jiří; Ludmila BARTLOVÁ; Lukáš MAREK a Michal FEDORA

Vydání

Česká a slovenská neurologie a neurochirurgie, Praha, ČLS JEP, 2010, 1210-7859

Další údaje

Jazyk

čeština

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 0.393

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/10:00051304

Organizační jednotka

Lékařská fakulta

UT WoS

Klíčová slova česky

protein S100; vážný úraz hlavy; výsledek; děti

Klíčová slova anglicky

S100protein; severe head injury; outcome; children

Příznaky

Mezinárodní význam
Změněno: 12. 4. 2012 12:22, Mgr. Michal Petr

Anotace

ORIG EN

V originále

S100B is a protein biomarker that reflects CNS injury. The aims of the current study were to investigate correlations between the initial level of serum S100B protein and mortality and computerized tomography (CT) findings, as well as to establish whether there is an association between S100B and Glasgow outcome scale (GOS) after six months. This prospective study enrolled 43 patients with traumatic brain injury (TBI), verified by computerized tomography and categorized by Marshall classification. Venous blood samples were taken on admission and every 24 h for a maximum of six consecutive days. The outcome was evaluated six months after TBI using the Glasgow outcome scale (GOS) in all patients. GOS was taken as principal end point for all predictive analyses. We demonstrated statistically significant relationships between groups of patients and increased incidence of some types of injury – intracranial bleeding, subdural haematoma, skull fracture, and oedema. The ratio of S100B in 2nd day/initial S100B value significantly differentiated between the groups of patients compared. Levels of S100B were elevated in patients with some specific types of injury, namely intracranial bleeding, subdural haematoma and oedema. The level of S100B was confirmed as a clinically valuable indicator of severity of injury and is proposed as an effective predictor of risk outcome (GOS = 1).

Anglicky

S100B is a protein biomarker that reflects CNS injury. The aims of the current study were to investigate correlations between the initial level of serum S100B protein and mortality and computerized tomography (CT) findings, as well as to establish whether there is an association between S100B and Glasgow outcome scale (GOS) after six months. This prospective study enrolled 43 patients with traumatic brain injury (TBI), verified by computerized tomography and categorized by Marshall classification. Venous blood samples were taken on admission and every 24 h for a maximum of six consecutive days. The outcome was evaluated six months after TBI using the Glasgow outcome scale (GOS) in all patients. GOS was taken as principal end point for all predictive analyses. We demonstrated statistically significant relationships between groups of patients and increased incidence of some types of injury – intracranial bleeding, subdural haematoma, skull fracture, and oedema. The ratio of S100B in 2nd day/initial S100B value significantly differentiated between the groups of patients compared. Levels of S100B were elevated in patients with some specific types of injury, namely intracranial bleeding, subdural haematoma and oedema. The level of S100B was confirmed as a clinically valuable indicator of severity of injury and is proposed as an effective predictor of risk outcome (GOS = 1).